Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone.

Bone and bone marrow are important sites of metastasis formation in breast cancer. Extracellular matrix proteins with attachment properties are generally believed to play a key role in tumorigenesis and metastasis formation. We have investigated whether mammary carcinoma cells (MDA-MB-231) can recognize constructs of the fairly bone-specific human bone sialoprotein, which encompass the RGD sequence (EPRGD-NYR). Exogenously added bone sialoprotein peptides with this amino acid sequence in their backbone structure, but not the more common fibronectin-derived GRGDS peptide, strongly inhibited breast cancer cell adhesion to extracellular bone matrix at micromolar concentrations. Most cyclic derivatives with the EPRGDNYR sequence were more effective inhibitors of tumor cell adhesion to bone than their linear equivalents. Furthermore, changes in the RGD-tripeptide of the backbone structure of the constructs, removal of the NYR flanking sequence, or a different tertiary cyclic structure significantly decreased their inhibitory potencies. In addition, the RGE-analogue EPRGENYR was capable of inhibiting breast cancer cell adhesion to bone, albeit to a lesser extent. We conclude therefore, that the inhibitory potency of the bone sialoprotein-derived peptides on breast cancer cell adhesion to bone is not solely due to a properly positioned RGD-motif alone but is also determined by its flanking regions, together with the tertiary structure of the EPRGDNYR peptide. Synthetic cyclic constructs with the EPRGDNYR sequence may, therefore, be potentially useful as antiadhesive agents for cancer cells to bone in vivo.

[1]  G. Hunter,et al.  Nucleation of hydroxyapatite by bone sialoprotein. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Stamp,et al.  Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. , 1992, Human pathology.

[3]  M. Olivé,et al.  Breast tumor cell lines from pleural effusions. , 1974, Journal of the National Cancer Institute.

[4]  V. Castronovo,et al.  Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. , 1994, Cancer research.

[5]  C. Galasko The development of skeletal metastases. , 1989, Nihon Seikeigeka Gakkai zasshi.

[6]  K. Chan,et al.  Cyclic RGD peptide analogues as antiplatelet antithrombotics. , 1992, Journal of medicinal chemistry.

[7]  L. Avioli,et al.  Matrix sialoprotein of developing bone. , 1983, The Journal of biological chemistry.

[8]  W. Grzesik,et al.  Bone matrix RGD glycoproteins: Immunolocalization and interaction with human primary osteoblastic bone cells in vitro , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  J. Sodek,et al.  Developmental expression of bone sialoprotein mRNA in rat mineralized connective tissues , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  Paterson Ah Bone metastases in breast cancer, prostate cancer and myeloma. , 1987 .

[11]  E. Bonucci,et al.  Localization of bone sialoprotein (BSP) to Golgi and post-Golgi secretory structures in osteoblasts and to discrete sites in early bone matrix. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  D. Heinegård,et al.  Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. , 1994, The Journal of biological chemistry.

[13]  L. Liotta,et al.  Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. , 1994, Current opinion in oncology.

[14]  D. Heinegård,et al.  Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. McKee,et al.  Bone sialoprotein mRNA expression and ultrastructural localization in fetal porcine calvarial bone: comparisons with osteopontin , 2004, The Histochemical Journal.

[16]  References , 1971 .

[17]  P. Delmas,et al.  Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells , 1994, The Journal of cell biology.

[18]  F. Reinholt,et al.  Distribution and synthesis of bone sialoprotein in metaphyseal bone of young rats show a distinctly different pattern from that of osteopontin. , 1994, European journal of cell biology.

[19]  M. Young,et al.  Bone matrix mRNA expression in differentiating fetal bovine osteoblasts , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  J. Sodek,et al.  Developmental expression of osteopontin (OPN) mRNA in rat tissues: evidence for a role for OPN in bone formation and resorption. , 1993, Matrix.

[21]  M J Bissell,et al.  Involvement of extracellular matrix constituents in breast cancer. , 1995, Seminars in cancer biology.

[22]  C. Löwik,et al.  Integrins and osteoclastic resorption in three bone organ cultures: Differential sensitivity to synthetic arg‐gly‐asp peptides during osteoclast formation , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  J. Brugge,et al.  Integrins and signal transduction pathways: the road taken. , 1995, Science.

[24]  E Ruoslahti,et al.  Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. , 1987, The Journal of biological chemistry.

[25]  A. V. van Oosterom,et al.  Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment. , 1986, European journal of cancer & clinical oncology.

[26]  E. Bonucci,et al.  Bone sialoprotein (BSP) secretion and osteoblast differentiation: relationship to bromodeoxyuridine incorporation, alkaline phosphatase, and matrix deposition. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[27]  J. Carter,et al.  Mechanisms of cancer metastasis to bone. , 1986, The Journal of bone and joint surgery. American volume.

[28]  A. Paterson Bone metastases in breast cancer, prostate cancer and myeloma. , 1987, Bone.

[29]  M. Horton,et al.  Integrin receptor-mediated mobilisation of intranuclear calcium in rat osteoclasts. , 1993, Journal of cell science.

[30]  B. Clarke,et al.  Distribution of noncollagenous proteins in the matrix of adult human bone: Evidence of anatomic and functional heterogeneity , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  M. Horton,et al.  Modulation of vitronectin receptor‐mediated osteoclast adhesion by Arg‐Gly‐Asp peptide analogs: A structure‐function analysis , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  J. Sodek,et al.  Temporal changes in matrix protein synthesis and mRNA expression during mineralized tissue formation by adult rat bone marrow cells in culture , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.